A plain language summary of the safety of relugolix combination therapy and improvement in symptoms in women with uterine fibroids from the LIBERTY 1 and LIBERTY 2 studies.

Ayman Al-Hendy,Andrea S Lukes,Alfred N Poindexter,Roberta Venturella,Claudio Villarroel,Hilary Od Critchley,Yulan Li,Laura McKain,Juan C Arjona Ferreira,Andria Gm Langenberg,Rachel B Wagman,Elizabeth A Stewart

Pain management（2023）

引用 0|浏览7

暂无评分

摘要

More women with uterine fibroids taking relugolix combination therapy for 24 weeks were likely to have fewer uterine fibroid symptoms than women receiving placebo. NCT03049735 (LIBERTY 1); NCT03103087 (LIBERTY 2).

查看译文

关键词

pain, relugolix, uterine fibroids

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要